Mizuho Securities analyst Difei Yang maintained a Buy rating on Nightstar Therapeutics Limited (NASDAQ: NITE) today and set a price target of $20. The company’s shares closed yesterday at $17.98.
Yang wrote:
“We expect upcoming data from the NSR-RPGR program, to be presented at the Specialists (EURETINA) 2018 meeting on 09/22/18, will be an important catalyst for the shares. Following this data, Nightstar will likely initiate an expansion study of NSR- RPGR in 4Q18 with data available in mid-2019.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 22.4% and a 53.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Nightstar Therapeutics Limited has an analyst consensus of Moderate Buy, with a price target consensus of $30, representing a 66.9% upside. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $40 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.94 and a one-year low of $10.01. Currently, Nightstar Therapeutics Limited has an average volume of 90.93K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.
